Genentech has the conjugates trastuzumab-MCC-DM1 [103] (phase 2), RG-7593 (anti-CD22-MCC-MMAE) (phase 1 for non-Hodgkin’s lymphoma), and lorvotuzumab-DM1, (anti CD56 mAb) (phase 2) in advanced trials. This evidence concerns the gene NCAM1 and non-Hodgkin lymphoma.